Gongwin Biopharm Holdings Co. Ltd.
Gongwin Biopharm Holdings Co., Ltd., a clinical-stage biopharmaceutical company, develops anticancer drugs in Hong Kong, China, and Singapore. It is developing PTS302, which has completed Phase III clinical trials for the treatment of lung cancer; PTS100, which is in Phase II clinical trials for the treatment of hepatocellular carcinoma; PTS02, which is in Phase I clinical trials for the treatmen… Read more
Gongwin Biopharm Holdings Co. Ltd. (6617) - Net Assets
Latest net assets as of : NT$- TWD
Based on the latest financial reports, Gongwin Biopharm Holdings Co. Ltd. (6617) has net assets worth NT$- TWD as of .
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (NT$-) and total liabilities (NT$-). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | NT$- |
| % of Total Assets | 0% |
| Annual Growth Rate | N/A |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | N/A |
Gongwin Biopharm Holdings Co. Ltd. - Net Assets Trend (None–None)
This chart illustrates how Gongwin Biopharm Holdings Co. Ltd.'s net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Gongwin Biopharm Holdings Co. Ltd. (None–None)
The table below shows the annual net assets of Gongwin Biopharm Holdings Co. Ltd. from None to None.
| Year | Net Assets | Change |
|---|---|---|
| No yearly data available. | ||
Equity Component Analysis
This analysis shows how different components contribute to Gongwin Biopharm Holdings Co. Ltd.'s total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- No equity composition insights available.
Gongwin Biopharm Holdings Co. Ltd. Competitors by Market Cap
The table below lists competitors of Gongwin Biopharm Holdings Co. Ltd. ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Cyient DLM Limited
NSE:CYIENTDLM
|
$129.69 Million |
|
Track & Field Co S.A
SA:TFCO4
|
$129.69 Million |
|
Sinphar Pharmaceutical Co Ltd
TW:1734
|
$129.70 Million |
|
Eastern & Oriental Bhd
KLSE:3417
|
$129.70 Million |
|
Jeju Air Co Ltd
KO:089590
|
$129.67 Million |
|
AKATSUKI INC.
F:7QT
|
$129.66 Million |
|
Hangzhou Gisway Information Technology Co. Ltd. A
SHE:301390
|
$129.65 Million |
|
Theratechnologies Inc.
NASDAQ:THTX
|
$129.60 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Gongwin Biopharm Holdings Co. Ltd.'s equity between the two most recent reporting periods.
Insufficient data available to analyze equity growth attribution.
Book Value vs Market Value Analysis
This analysis compares Gongwin Biopharm Holdings Co. Ltd.'s book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Insufficient data available to analyze book value vs market value.
Capital Efficiency Dashboard
This dashboard shows how efficiently Gongwin Biopharm Holdings Co. Ltd. utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Insufficient data available to analyze capital efficiency metrics.
Industry Comparison
This section compares Gongwin Biopharm Holdings Co. Ltd.'s net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $1,057,086,200
- Average return on equity (ROE) among peers: 8.07%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Gongwin Biopharm Holdings Co. Ltd. (6617) | NT$- | N/A | N/A | $129.68 Million |
| Synbio Tech Inc. (1295) | $863.17 Million | 18.53% | 0.78x | $21.14K |
| Apex Biotechnology Corp (1733) | $1.92 Billion | 19.33% | 0.42x | $65.42 Million |
| Sinphar Pharmaceutical Co Ltd (1734) | $1.77 Billion | 2.60% | 1.02x | $129.70 Million |
| Panion & BF Biotech Inc (1760) | $835.25 Million | 10.84% | 0.49x | $122.27 Million |
| Chunghwa Chemical Synthesis & Biotech Co Ltd (1762) | $1.62 Billion | 0.90% | 0.98x | $40.94 Million |
| SYN-Tech Chem & Pharm Co Ltd (1777) | $1.10 Billion | 14.01% | 0.66x | $45.00 Million |
| Level Biotechnology (3118) | $542.40 Million | 10.78% | 0.50x | $22.42 Million |
| GenMont Biotech Inc (3164) | $737.87 Million | 20.00% | 0.85x | $30.93 Million |
| Medigen Biotechnology (3176) | $650.39 Million | 0.00% | 0.08x | $90.59 Million |
| Sagittarius Life Science (3205) | $531.71 Million | -16.25% | 0.27x | $56.62 Million |